/
ARGX
$924.52+$12.06 (+1.32%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$55.2B
62M shares
52-week range
$510.06 – $934.62
98% from low
Exchange
NASDAQ
ADRC
Borrow rate
0.26%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$620.04
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $24.6M | $78.5M | $41.2M | $497.3M | $410.7M | $1.23B | $2.19B | $4.15B |
| Cost of revenue | $0 | $0 | $0 | $580.5M | $29.4M | $117.8M | $227.3M | $450.7M |
| Gross profit | $24.6M | $78.5M | $41.2M | $497.3M | $381.3M | $1.11B | $1.96B | $3.70B |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 92.8% | 90.4% | 89.6% | 89.1% |
| R&D | $95.6M | $220.8M | $370.5M | $580.5M | $663.4M | $859.5M | $983.4M | $1.36B |
| Operating income | −$93.6M | −$198.9M | −$477.6M | −$348.7M | −$720.3M | −$425.0M | −$21.7M | $1.05B |
| EBITDA | −$93.1M | −$173.4M | −$601.0M | −$392.8M | −$622.8M | −$192.3M | $105.2M | $1.31B |
| Net income | −$76.2M | −$181.2M | −$608.5M | −$407.6M | −$709.6M | −$295.1M | $833.0M | $1.29B |
| Net margin | -310.2% | -231.0% | -1475.3% | -82.0% | -172.8% | -24.1% | 38.0% | 31.1% |
| EPS (diluted) | -2.12 | -4.69 | -13.40 | -7.99 | -13.05 | -5.16 | 12.78 | 19.63 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $6.0B | $26.43 | $23.29–$29.75 | 13 |
| 2027 | $7.3B | $35.79 | $28.84–$41.63 | 13 |
| 2028 | $8.6B | $44.47 | $41.53–$51.38 | 9 |
| 2029 | $9.9B | $53.90 | $50.35–$62.28 | 11 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
argenx SE American Depositary Shares
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
www.argenx.com- Employees
- 1,863
- IPO / List date
- May 18, 2017
Held by traders on TradeandTell
No one on the platform currently holds ARGX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Bridgewater Associatesas of 2026-03-31 | 1,214 | $886.5K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ARGX yet.
